

10/763,105

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,
STN AnaVist, now available
NEWS 4 AUG 11 Derwent World Patents Index(R) web-based training during
August
NEWS 5 AUG 11 STN AnaVist workshops to be held in North America
NEWS 6 AUG 30 CA/CAPLUS - Increased access to 19th century research documents
NEWS 7 AUG 30 CASREACT - Enhanced with displayable reaction conditions
NEWS 8 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:39:47 ON 18 SEP 2005

=>

=>

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 16:40:13 ON 18 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

10/763,105

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 SEP 2005 HIGHEST RN 863378-74-9
DICTIONARY FILE UPDATES: 16 SEP 2005 HIGHEST RN 863378-74-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Documents and Settings\VBalasubramania\My Documents\STNEXP4\QUERIES\10763105.str



chain nodes :
10 11 12 13 14 15 16 22
ring nodes :
1 2 3 4 5 6 7 8 9 23 24 25 26 27 28
chain bonds :
2-22 4-23 8-10 9-11 13-16 14-15

10/763,105

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 23-24 23-28 24-25 25-26 26-27
27-28

exact/norm bonds :

1-2 1-6 2-3 2-22 3-4 4-5 4-23 5-6 5-7 6-9 7-8 8-9 8-10 9-11 13-16
14-15 23-24 23-28 24-25 25-26 26-27 27-28

G1:H, [*1], [*2], [*3]

G2:C,O,S

Connectivity :

12:1 E exact RC ring/chain 13:1 E exact RC ring/chain 14:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 22:CLASS 23:Atom

24:Atom 25:Atom 26:Atom 27:Atom 28:Atom

Generic attributes :

10:

Saturation : Unsaturated

11:


Saturation : Unsaturated

L1 STRUCTURE UPLOADED

=> D L1

L1 HAS NO ANSWERS

L1 STR



G1 H, [01], [02], [03]

G2 C,O,S

Structure attributes must be viewed using STN Express query preparation.

10/763,105

=> S L1 SSS SAM

SAMPLE SEARCH INITIATED 16:40:39 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 54 TO ITERATE

100.0% PROCESSED 54 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 640 TO 1520

PROJECTED ANSWERS: 2 TO 124


L2 2 SEA SSS SAM L1

=> D SCAN

L2 2 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-ethylphenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI)

MF C26 H28 Cl N7 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN

IN Ethanone, 1-[1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-phenyl-4-piperidinyl]- (9CI)

MF C31 H27 Cl2 N5 O

10/763,105



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> S L1 SSS FUL

FULL SEARCH INITIATED 16:40:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1082 TO ITERATE

100.0% PROCESSED 1082 ITERATIONS

49 ANSWERS

SEARCH TIME: 00.00.01

L3 49 SEA SSS FUL L1

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

161.33

161.54

FILE 'CAPLUS' ENTERED AT 16:41:02 ON 18 SEP 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Sep 2005 VOL 143 ISS 13

FILE LAST UPDATED: 16 Sep 2005 (20050916/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

10/763,105

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> S L3

L4 2 L3

=> D L4 1-2 BIB HITSTR

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:160837 CAPLUS

DN 142:233372

TI Pharmaceutical composition using a combination of an opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal

IN Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 25 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005043327	A1	20050224	US 2004-870209	20040617
	WO 2005018645	A1	20050303	WO 2004-IB2596	20040809
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2003-496803P P 20030821

IT 736993-30-9 736993-50-3 736993-51-4
736993-52-5 736993-53-6 736993-54-7
736993-55-8 736993-56-9 736993-57-0
736993-58-1 736993-63-8 736993-64-9
736993-65-0 736993-66-1 736993-67-2
736993-68-3 736993-69-4 736993-70-7
736994-31-3 845670-45-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)

RN 736993-30-9 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(methylsulfonyl)-, (1S,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/763,105



RN 736993-50-3 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)



RN 736993-51-4 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-52-5 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736993-53-6 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-54-7 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736993-55-8 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-56-9 CAPLUS


CN 3-Azetidinecarboxamide, 3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 736993-57-0 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(methylamino)- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-58-1 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 736993-63-8 CAPLUS


CN Ethanone, 1-[1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-phenyl-4-piperidinyl]- (9CI) (CA INDEX NAME)

10/763,105




RN 736993-64-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 736993-65-0 CAPLUS

CN 4-Piperidinol, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 736993-66-1 CAPLUS


CN 4-Piperidinol, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 736993-67-2 CAPLUS


CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-methyl- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-68-3 CAPLUS


CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 736993-69-4 CAPLUS


CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-70-7 CAPLUS


CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-6,6-dimethyl- (9CI) (CA INDEX NAME)



RN 736994-31-3 CAPLUS


CN Pyrazolo[1,5-a]-1,3,5-triazine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)

10/763,105



RN 845670-45-3 CAPLUS

CN Pyrazolo[1,5-a]-1,3,5-triazine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:654773 CAPLUS

DN 141:190806

TI Preparation of pyrazolotriazines as cannabinoid CB1 receptor antagonists

IN Griffith, David A.

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 72 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157839	A1	20040812	US 2004-763105	20040121
	WO 2004069837	A1	20040819	WO 2004-IB269	20040126
W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				

10/763,105

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

NL 1025404 A1 20040809 NL 2004-1025404 20040204
NL 1025404 C2 20050314
PRAI US 2003-445728P P 20030206
OS MARPAT 141:190806
IT 736993-30-9P 736993-35-4P 736993-36-5P
736993-37-6P 736993-38-7P 736993-40-1P
736993-41-2P 736993-42-3P 736993-43-4P
736993-44-5P 736993-45-6P 736993-46-7P
736993-47-8P 736993-48-9P 736993-49-0P
736993-50-3P 736993-51-4P 736993-52-5P
736993-53-6P 736993-54-7P 736993-55-8P
736993-56-9P 736993-57-0P 736993-58-1P
736993-59-2P 736993-60-5P 736993-61-6P
736993-62-7P 736993-63-8P 736993-64-9P
736993-65-0P 736993-66-1P 736993-67-2P
736993-68-3P 736993-69-4P 736993-70-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of pyrazolotriazines as cannabinoid CB1 receptor antagonists)
RN 736993-30-9 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(methylsulfonyl)-, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-35-4 CAPLUS
CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, 1,1-dimethylethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/763,105



RN 736993-36-5 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 736993-37-6 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-acetyl-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/763,105



RN 736993-38-7 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(2-methyl-1-oxopropyl)-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 736993-40-1 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-benzoyl-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/763,105



RN 736993-41-2 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(ethylsulfonyl)-, (1S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 736993-42-3 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-[(1-methylethyl)sulfonyl]-, (1S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/763,105



RN 736993-43-4 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-sulfonamide, 5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-N,N-dimethyl-, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-44-5 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(2,4-dichlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)

10/763,105




RN 736993-45-6 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7,8-bis(2-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736993-46-7 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-cyanophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



10/763,105


RN 736993-47-8 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-2-methyl-8-(4-methylphenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736993-48-9 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-ethylphenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736993-49-0 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-methoxyphenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-50-3 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)



RN 736993-51-4 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-52-5 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736993-53-6 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-54-7 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736993-55-8 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

Abstract The purpose of this study was to determine whether there were differences in the prevalence of self-reported depression between men and women who had been exposed to violence by intimate partners. Data from the National Longitudinal Study of Women's Health are used. Results show that among women who reported being sexually abused by their current or former partner, 10% reported having experienced depression during the past year compared to 6% of those who did not report sexual abuse. Among women who reported physical abuse by their current or former partner, 17% reported experiencing depression during the past year compared to 8% of those who did not report physical abuse. These results suggest that exposure to violence by intimate partners is associated with higher rates of self-reported depression.



RN 736993-56-9 CAPLUS


3-Azetidinecarboxamide, 3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 736993-57-0 CAPLUS


CN	3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(methylamino)- (9CI) (CA INDEX NAME)
----	---

10/763,105



RN 736993-58-1 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 736993-59-2 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-60-5 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI)
(CA INDEX NAME)



RN 736993-61-6 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI)
(CA INDEX NAME)

10/763,105



RN 736993-62-7 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(methylamino)- (9CI)
(CA INDEX NAME)



RN 736993-63-8 CAPLUS


CN Ethanone, 1-[1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-phenyl-4-piperidinyl]- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-64-9 CAPLUS


CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 736993-65-0 CAPLUS


CN 4-Piperidinol, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-66-1 CAPLUS


CN 4-Piperidinol, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 736993-67-2 CAPLUS


CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-methyl- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-68-3 CAPLUS


CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)



RN 736993-69-4 CAPLUS


CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

10/763,105



RN 736993-70-7 CAPLUS

CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-6,6-dimethyl- (9CI) (CA INDEX NAME)



IT 736994-23-3P 736994-24-4P 736994-25-5P

736994-26-6P 736994-27-7P 736994-29-9P

736994-30-2P 736994-31-3P 736994-32-4P

736994-33-5P 736994-34-6P 736994-35-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolotriazines as cannabinoid CB1 receptor antagonists)

RN 736994-23-3 CAPLUS


CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)-, hydrochloride (9CI) (CA INDEX NAME)

10/763,105



RN 736994-24-4 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 736994-25-5 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 736993-54-7

CMF C24 H23 Cl2 N7 O


10/763,105



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 736994-26-6 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 736993-54-7

CMF C24 H23 Cl2 N7 O




10/763,105

CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 736994-27-7 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl


RN 736994-29-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)-, hydrochloride (9CI) (CA INDEX NAME)

10/763,105




RN 736994-30-2 CAPLUS
 CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(3-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736994-31-3 CAPLUS
 CN Pyrazolo[1,5-a]-1,3,5-triazine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)


10/763,105



RN 736994-32-4 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, dihydrochloride, (1S,4S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 736994-33-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, (1 α ,5 α ,6 α)-
(9CI) (CA INDEX NAME)

Relative stereochemistry.


10/763,105



RN 736994-34-6 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(ethylsulfonyl)-, dihydrochloride, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 736994-35-7 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, 5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-N,N-dimethyl-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/763,105



=> LOG Y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE

ENTRY



7.23

TOTAL

SESSION

168.77

STN INTERNATIONAL LOGOFF AT 16:41:21 ON 18 SEP 2005



chain nodes :

10 11 12 13 14 15 16 22

ring nodes :

1 2 3 4 5 6 7 8 9 23 24 25 26 27 28

chain bonds :

2-22 4-23 8-10 9-11 13-16 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 23-24 23-28 24-25 25-26 26-27 27-28

exact/norm bonds :

1-2 1-6 2-3 2-22 3-4 4-5 4-23 5-6 5-7 6-9 7-8 8-9 8-10 9-11 13-16 14-15

23-24 23-28 24-25 25-26 26-27 27-28

G1:H, [*1], [*2], [*3]

G2:C,O,S

Connectivity :

12:1 E exact RC ring/chain 13:1 E exact RC ring/chain 14:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom

12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom

26:Atom 27:Atom 28:Atom



Generic attributes :

10:

Saturation : Unsaturated

11:

Saturation : Unsaturated



chain nodes :

10 11 12 13 14 15 16 22

ring nodes :

1 2 3 4 5 6 7 8 9 23 24 25 26 27 28

chain bonds :

2-22 4-23 8-10 9-11 13-16 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 23-24 23-28 24-25 25-26 26-27 27-28

exact/norm bonds :

1-2 1-6 2-3 2-22 3-4 4-5 4-23 5-6 5-7 6-9 7-8 8-9 8-10 9-11 13-16 14-15
23-24 23-28 24-25 25-26 26-27 27-28

G1:H, [*1], [*2], [*3]

G2:C,O,S

Connectivity :

12:1 E exact RC ring/chain 13:1 E exact RC ring/chain 14:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom
26:Atom 27:Atom 28:Atom

Generic attributes :

10:
Saturation : Unsaturated
11:
Saturation : Unsaturated